CLAIMS

1. A combination comprising :

a compound A which is selected from:

N-cyclopropyl-4-{6-[1-(3-fluoro-4-methoxyphenyl)ethenyl]-8-[(3,3,3-trifluoropropyl)amino]imidazo[1,2-*b*]pyridazin-3-yl}-2-methylbenzamide,

N-cyclopropyl-4-{6-[difluoro(3-fluoro-4-methoxyphenyl)methyl]-8-[(3,3,3-trifluoropropyl)amino]imidazo[1,2-*b*]pyridazin-3-yl}-2-methylbenzamide,

(*RS*)-*N*-cyclopropyl-4-{6-[(3-fluoro-2-hydroxyphenyl)(hydroxy)methyl]-8-[(3,3,3-trifluoropropyl)amino]imidazo[1,2-*b*]pyridazin-3-yl}-2-methylbenzamide,

(*R*)-*N*-cyclopropyl-4-{6-[(3-fluoro-2-hydroxyphenyl)(hydroxy)methyl]-8-[(3,3,3-trifluoropropyl)amino]imidazo[1,2-*b*]pyridazin-3-yl}-2-methylbenzamide,

(*S*)-*N*-cyclopropyl-4-{6-[(3-fluoro-2-hydroxyphenyl)(hydroxy)methyl]-8-[(3,3,3-trifluoropropyl)amino]imidazo[1,2-*b*]pyridazin-3-yl}-2-methylbenzamide,

(*RS*)-*N*-cyclopropyl-4-{6-[1-(3-fluoro-2-hydroxyphenyl)-1-hydroxyethyl]-8-[(3,3,3-trifluoropropyl)amino]imidazo[1,2-*b*]pyridazin-3-yl}-2-methylbenzamide,

(*R*)-*N*-cyclopropyl-4-{6-[1-(3-fluoro-2-hydroxyphenyl)-1-hydroxyethyl]-8-[(3,3,3-trifluoropropyl)amino]imidazo[1,2-*b*]pyridazin-3-yl}-2-methylbenzamide,

(*S*)-*N*-cyclopropyl-4-{6-[1-(3-fluoro-2-hydroxyphenyl)-1-hydroxyethyl]-8-[(3,3,3-trifluoropropyl)amino]imidazo[1,2-*b*]pyridazin-3-yl}-2-methylbenzamide,

(*RS*)-*N*-cyclopropyl-4-{6-[fluoro(3-fluorophenyl)methyl]-8-[(3,3,3-trifluoropropyl)amino]imidazo[1,2-*b*]pyridazin-3-yl}-2-methylbenzamide,

(*R*)-*N*-cyclopropyl-4-{6-[fluoro(3-fluorophenyl)methyl]-8-[(3,3,3-trifluoropropyl)amino]imidazo[1,2-*b*]pyridazin-3-yl}-2-methylbenzamide,

(*S*)-*N*-cyclopropyl-4-{6-[fluoro(3-fluorophenyl)methyl]-8-[(3,3,3-trifluoropropyl)amino]imidazo[1,2-*b*]pyridazin-3-yl}-2-methylbenzamide,

N-cyclopropyl-4-{6-[difluoro(3-fluorophenyl)methyl]-8-[(3,3,3-trifluoropropyl)amino]imidazo[1,2-*b*]pyridazin-3-yl}-2-methylbenzamide,

N-cyclopropyl-4-{6-(3-methoxybenzoyl)-8-[(3,3,3-trifluoropropyl)amino]imidazo[1,2-*b*]pyridazin-3-yl}-2-methylbenzamide,

N-cyclopropyl-4-{6-[1-(3-methoxyphenyl)vinyl]-8-[(3,3,3-trifluoropropyl)amino]imidazo[1,2-*b*]pyridazin-3-yl}-2-methylbenzamide,

N-cyclopropyl-4-{6-(4-methoxybenzoyl)-8-[(3,3,3-trifluoropropyl)amino]imidazo[1,2-*b*]pyridazin-3-yl}-2-methylbenzamide,

N-cyclopropyl-4-{6-[1-(4-methoxyphenyl)vinyl]-8-[(3,3,3-trifluoropropyl)amino]imidazo[1,2-*b*]pyridazin-3-yl}-2-methylbenzamide,

N-cyclopropyl-4-{6-[(2,5-difluorophenyl)(hydroxy)methyl]-8-[(3,3,3-trifluoropropyl)amino]imidazo[1,2-*b*]pyridazin-3-yl}-2-methylbenzamide,

N-cyclopropyl-4-{6-(2,5-difluorobenzoyl)-8-[(3,3,3-trifluoropropyl)amino]imidazo[1,2-*b*]pyridazin-3-yl}-2-methylbenzamide,

N-cyclopropyl-4-{6-(3-fluoro-4-methoxybenzoyl)-8-[(3,3,3-trifluoropropyl)amino]imidazo[1,2-*b*]pyridazin-3-yl}-2-methylbenzamide,

N-cyclopropyl-4-{6-(2,3-difluorobenzoyl)-8-[(3,3,3-trifluoropropyl)amino]imidazo[1,2-*b*]pyridazin-3-yl}-2-methylbenzamide,

N-cyclopropyl-4-{6-[1-(2,3-difluorophenyl)vinyl]-8-[(3,3,3-trifluoropropyl)amino]imidazo[1,2-*b*]pyridazin-3-yl}-2-methylbenzamide,

N-cyclopropyl-4-{6-[difluoro(4-methoxyphenyl)methyl]-8-[(3,3,3-trifluoropropyl)amino]imidazo[1,2-*b*]pyridazin-3-yl}-2-methylbenzamide,

N-cyclopropyl-4-{6-[1-(2,3-difluorophenyl)cyclopropyl]-8-[(3,3,3-trifluoropropyl)amino]imidazo[1,2-*b*]pyridazin-3-yl}-2-methylbenzamide,

N-cyclopropyl-4-{6-[(2,3-difluorophenyl)(difluoro)methyl]-8-[(3,3,3-trifluoropropyl)amino]imidazo[1,2-*b*]pyridazin-3-yl}-2-methylbenzamide,

N-cyclopropyl-4-{6-[1-(2,5-difluorophenyl)vinyl]-8-[(3,3,3-trifluoropropyl)amino]imidazo[1,2-*b*]pyridazin-3-yl}-2-methylbenzamide,

N-cyclopropyl-4-{6-[1-(2,5-difluorophenyl)cyclopropyl]-8-[(3,3,3-trifluoropropyl)amino]imidazo[1,2-*b*]pyridazin-3-yl}-2-methylbenzamide,

N-cyclopropyl-4-{6-[(2,5-difluorophenyl)(difluoro)methyl]-8-[(3,3,3-trifluoropropyl)amino]imidazo[1,2-*b*]pyridazin-3-yl}-2-methylbenzamide,

N-cyclopropyl-4-{6-[1-(5-fluoro-2-hydroxyphenyl)ethenyl]-8-[(3,3,3-trifluoropropyl)amino]imidazo[1,2-*b*]pyridazin-3-yl}-2-methylbenzamide,

N-cyclopropyl-4-{6-[1-(5-fluoro-2-hydroxyphenyl)cyclopropyl]-8-[(3,3,3-trifluoropropyl)amino]imidazo[1,2-*b*]pyridazin-3-yl}-2-methylbenzamide,

N-cyclopropyl-4-{6-(3-fluoro-4-methoxyphenoxy)-8-[(oxetan-3-ylmethyl)amino]imidazo[1,2-*b*]pyridazin-3-yl}-2-methylbenzamide,

N-cyclopropyl-4-{6-(2,3-difluoro-4-methoxyphenoxy)-8-[(3,3,3-trifluoropropyl)amino]imidazo[1,2-*b*]pyridazin-3-yl}-2-methylbenzamide, and

N-cyclopropyl-4-{6-(2,3-difluoro-4-methoxyphenoxy)-8-[(tetrahydro-2*H*-pyran-4-ylmethyl)amino]imidazo[1,2-*b*]pyridazin-3-yl}-2-methylbenzamide,

or a salt thereof

and

one or more mitotic inhibitors selected from docetaxel and paclitaxel.

2. The combination according to claim 1, wherein the compound A is selected from:

N-cyclopropyl-4-{6-[1-(5-fluoro-2-hydroxyphenyl)cyclopropyl]-8-[(3,3,3-trifluoropropyl)amino]imidazo[1,2-*b*]pyridazin-3-yl}-2-methylbenzamide,

N-cyclopropyl-4-{6-(3-fluoro-4-methoxyphenoxy)-8-[(oxetan-3-ylmethyl)amino]imidazo[1,2-*b*]pyridazin-3-yl}-2-methylbenzamide,

N-cyclopropyl-4-{6-(2,3-difluoro-4-methoxyphenoxy)-8-[(3,3,3-trifluoropropyl)amino]imidazo[1,2-*b*]pyridazin-3-yl}-2-methylbenzamide, and

N-cyclopropyl-4-{6-(2,3-difluoro-4-methoxyphenoxy)-8-[(tetrahydro-2*H*-pyran-4-ylmethyl)amino]imidazo[1,2-*b*]pyridazin-3-yl}-2-methylbenzamide,

or a salt thereof, or a mixture of same.

3. The combination according to claim 1 or 2, wherein the compound A is *N*-cyclopropyl-4-{6-[1-(5-fluoro-2-hydroxyphenyl)cyclopropyl]-8-[(3,3,3-trifluoropropyl)amino]imidazo[1,2-*b*]pyridazin-3-yl}-2-methylbenzamide, or a salt thereof.

4. The combination according to claim 1 or 2, wherein the compound A is *N*-cyclopropyl-4-{6-(3-fluoro-4-methoxyphenoxy)-8-[(oxetan-3-ylmethyl)amino]imidazo[1,2-*b*]pyridazin-3-yl}-2-methylbenzamide,
or a salt thereof.

5. The combination according to claim 1 or 2, wherein the compound A is *N*-cyclopropyl-4-{6-(2,3-difluoro-4-methoxyphenoxy)-8-[(3,3,3-trifluoropropyl)amino]imidazo[1,2-*b*]pyridazin-3-yl}-2-methylbenzamide,
or a salt thereof.

6. The combination according to claim 1 or 2, wherein the compound A is *N*-cyclopropyl-4-{6-(2,3-difluoro-4-methoxyphenoxy)-8-[(tetrahydro-2*H*-pyran-4-ylmethyl)amino]imidazo[1,2-*b*]pyridazin-3-yl}-2-methylbenzamide, or a salt thereof.

7. The combination according to any one of claims 1 to 6 for use in the treatment or prophylaxis of pancreatic cancer, glioblastoma, ovarian cancer, non-small cell lung carcinoma, breast cancer and/or gastric cancer.

8. The use of a combination according to any one of claims 1 to 6 in the manufacture of a medicament for the treatment or prophylaxis of pancreatic cancer, glioblastoma, ovarian cancer, non-small cell lung carcinoma, breast cancer and/or gastric cancer.

9. A kit comprising a combination of :

component A : one or more compounds A, as defined in any one of claims 1 to 6;

and

component B : one or more mitotic inhibitors selected from docetaxel and paclitaxel;

and, optionally, one or more further pharmaceutical agents C; in which optionally all or either of said components A and B are in the form of a pharmaceutical formulation which is ready for use to be administered simultaneously, concurrently, separately or sequentially.